로딩 중…
지수 로딩 중…
Ardelyx, Inc.
ARDX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$4.98+0.61%
2026-08-03
Financials
Valuation Metrics
Ardelyx, Inc.'s Market Cap is $1.23B. At end of 2025 it was $1.42B. Ranked #2370 of 3,111 in US market (top 76%), #948 of 1,445 on NASDAQ (top 66%), #176 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.23B | US#2,370/3,111 Sec#176/269 |
| Revenue | $428M | US#2,424/3,111 Sec#84/269 |
| Net Income | $-58M | US—/3,111 Sec—/269 |
| Total Assets | $505M | US#2,748/3,111 Sec#158/269 |
| Net Assets | $149M | US#2,813/3,111 Sec#216/269 |
| Value | ||
| P/B | 8.28x | US#2,520/3,111 Sec#193/269 |
| P/S | 2.88x | US#1,710/3,111 Sec#48/269 |
| FCF Yield | -3.05% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -39.07% | US#2,697/3,111 Sec#154/269 |
| ROA | -11.51% | US#2,676/3,111 Sec#108/269 |
| Op. Margin | -8.75% | US#2,627/3,111 Sec#97/269 |
| Revenue Growth | 27.47% | US#541/3,111 Sec#72/269 |
| Financial Health | ||
| Debt Ratio | 239.46% | US#1,958/3,111 Sec#211/269 |
| Total Debt | $208M | US#2,200/3,111 Sec#90/269 |
| FCF | $-37M | US#2,448/3,111 Sec#108/269 |
| Cash | $31M | US#2,762/3,111 Sec#252/269 |
| Current Ratio | 3.49x | US#674/3,111 Sec#184/269 |
| Performance | ||
| 1Y Return | 15.01% | US#1,523/3,111 Sec#171/269 |
| 1M Return | -5.50% | US#2,028/3,111 Sec#141/269 |
| From 52W High | -40.71% | US#2,521/3,111 Sec#198/269 |
| 1Y MDD | -38.05% | US#1,853/3,111 Sec#135/269 |
| Trading | ||
| Volume | 2,886,886 shares | US#651/3,111 Sec#50/269 |
| Trading Value | $14M | US#2,149/3,111 Sec#170/269 |
| Per Share | ||
| EPS | $-0.25 | US—/3,111 Sec—/269 |
| BPS | $0.69 | US#2,670/3,111 Sec#215/269 |